Oncolytics Biotech Inc. (ONCY)

Oncolytics Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	34.91	11.67	41.26	31.22	14.15
Short-Term Investments	0	20.47	0	0	0
Cash & Cash Equivalents	34.91	32.14	41.26	31.22	14.15
Cash Growth	8.63%	-22.11%	32.17%	120.66%	3.27%
Receivables	0.02	0.52	0.87	0.09	2.07
Other Current Assets	3.25	3.03	2.78	2.43	2.71
Total Current Assets	38.17	35.68	44.9	33.74	18.93
Property, Plant & Equipment	0.65	0.65	0.98	0.61	0.73
Other Long-Term Assets	0	1	0	0	0
Total Long-Term Assets	0.65	1.65	0.98	0.61	0.73
Total Assets	38.82	37.33	45.88	34.35	19.66
Accounts Payable	3.57	3.65	1.99	1.81	3.17
Current Debt	0.13	0.22	0.29	0.25	0.34
Other Current Liabilities	0.53	0.08	0.41	0.66	9.36
Total Current Liabilities	4.24	3.95	2.69	2.71	12.87
Long-Term Debt	0.29	0.16	0.36	0.15	0.17
Other Long-Term Liabilities	6.73	6.73	6.73	6.73	6.73
Total Long-Term Liabilities	7.02	6.89	7.09	6.88	6.9
Total Liabilities	11.26	10.83	9.78	9.59	19.77
Total Debt	0.42	0.37	0.66	0.4	0.51
Debt Growth	13.40%	-43.05%	62.91%	-20.58%	-
Retained Earnings	-446	-418.25	-393.42	-367.11	-344.61
Comprehensive Income	0.54	0.66	0.39	0.4	0.46
Shareholders' Equity	27.56	26.5	36.1	24.75	-0.11
Net Cash / Debt	34.49	31.77	40.61	30.82	13.64
Net Cash / Debt Growth	8.58%	-21.77%	31.77%	125.91%	-0.42%
Net Cash Per Share	0.51	0.55	0.76	0.76	0.62
Working Capital	33.94	31.74	42.21	31.03	6.06
Book Value Per Share	0.41	0.46	0.68	0.61	-0.01

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).